tert-butyl 4-(2,3-difluorophenyl)-2,2-dimethyl-5-oxopiperazine-1-carboxylate | 1388626-44-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl 4-(2,3-difluorophenyl)-2,2-dimethyl-5-oxopiperazine-1-carboxylate
• CAS: 1388626-44-5
• 化学式: C₁₇H₂₂F₂N₂O₃
• 分子量: 340.37
• InChiKey: GXVBUAZWHIRPHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.33
• 重原子数：
  24.0
• 可旋转键数：
  1.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  49.85
• 氢给体数：
  0.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(2,3-difluorophenyl)-2,2-dimethyl-5-oxopiperazine-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 1-(2,3-difluorophenyl)-5,5-dimethylpiperazin-2-one
  参考文献：
  名称：

  Design and optimization of novel (2S,4S,5S)-5-amino-6-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)-4-hydroxy-2-isopropylhexanamides as renin inhibitors

  摘要：

  Introduction of the 2,2-dimethyl-4-phenylpiperazin-5-one scaffold into the P-3-P-1 portion of the (2S,4S,5S)-5-amino-6-dialkylamino-4-hydroxy-2-isopropylhexanamide backbone dramatically increased the renin inhibitory activity without using the interaction to the S-3(sp) pocket. Compound 31 exhibited >10,000-fold selectivity over other human proteases, and 18.5% oral bioavailability in monkey. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.05.092
• 作为产物：
  描述：

  tert-butyl (1-((2,3-difluorophenyl)amino)-2-methylpropan-2-yl)carbamate 在 potassium tert-butylate 作用下， 以 四氢呋喃 、 N,N-二甲基乙酰胺 为溶剂， 生成 tert-butyl 4-(2,3-difluorophenyl)-2,2-dimethyl-5-oxopiperazine-1-carboxylate
  参考文献：
  名称：

  Design and optimization of novel (2S,4S,5S)-5-amino-6-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)-4-hydroxy-2-isopropylhexanamides as renin inhibitors

  摘要：

  Introduction of the 2,2-dimethyl-4-phenylpiperazin-5-one scaffold into the P-3-P-1 portion of the (2S,4S,5S)-5-amino-6-dialkylamino-4-hydroxy-2-isopropylhexanamide backbone dramatically increased the renin inhibitory activity without using the interaction to the S-3(sp) pocket. Compound 31 exhibited >10,000-fold selectivity over other human proteases, and 18.5% oral bioavailability in monkey. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.05.092